Robert M. Davis - 29 Apr 2025 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
Chairman, CEO & President, Director
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Robert M. Davis
Issuer symbol
MRK
Transactions as of
29 Apr 2025
Transactions value $
$0
Form type
4
Filing time
01 May 2025, 18:07:59 UTC
Previous filing
29 Jan 2025
Next filing
05 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRK Common Stock 444K 29 Apr 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Restricted Stock Unit Award $0 +39.9K $0.00 39.9K 29 Apr 2025 Common Stock 39.9K Direct F1, F2
transaction MRK Stock Option (Right to Buy) Award $0 +182K $0.00 182K 29 Apr 2025 Common Stock 182K $84.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2 These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.
F3 The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.